If the pandemic made anything clear, it was that mental health support and treatment are severely limited. However, just as research into Covid-19 accelerated efforts for treatment for other physical illnesses, it also provided a need and opportunity for mental healthcare innovations.

One such exciting development in mental health support comes from Fisher Wallace and its brain stimulation wearable. This FDA-cleared technology helps treat some of the most common and debilitating mental illnesses like depression, anxiety and insomnia. Wearables like what Fisher Wallace is producing are the next stage for healthcare innovation because they effectively treat the problem without the frustrating and often painful side effects that come with many medications.

The State of American Healthcare Innovation

The CDC estimates that 40-46% of Americans suffer from depression. That number represents a massive audience who could benefit from treatment that doesn’t ask them to deal with side effects, make hefty monthly payments or do anything more than wear their treatment for 20 minutes once or twice a day. The status quo for mental healthcare is clunky, expensive and inefficient in terms of time and variable results. Many people suffering from depression still experience symptoms for years after they started a treatment process, even if they are regularly attending therapy and taking medication. In a study of 392 users of a Fisher Wallace Wearable at a Phoenix House Drug and Alcohol Rehabilitation Center, rehab retention increased by 50%. The national average for rehab retention is estimated to be around 30%.

What a Fisher Wallace Wearable Can Do

When using a Fisher Wallace wearable, the timeline for improvement is significantly shorter than many current therapeutic methods. The ambiguous timeline of traditional mental healthcare coupled with the meteoric rise in demand for mental health workers means a tested, affordable and accessible treatment method is called for and will be received eagerly. Fisher Wallace has some of the first hardware that can contend with drug therapy for the same mental illnesses that spread during the pandemic, but it is more cost-effective and doesn’t come with any of the side effects that make medical treatment for mental illness a lose-lose tradeoff for millions of people. Fisher Wallace is set to change the market for psychotherapy and drug treatment for mental health and is already being prescribed by 14,000 providers.

If you are personally, altruistically or academically interested in the healthcare innovations that came out of the pandemic, then consider investing in Fisher Wallace. The need for accessible mental health support is more present than ever in the United States alone. A device that has been proven to treat the mental illnesses that grew in the pandemic would have substantial effects on American emotional health and could inspire economic regrowth after the waves of unemployment and the depression that followed. If you are interested in investing in Fisher Wallace and contributing to some of the first hardware mental health treatment, then you can get a free device without a prescription under their wellness brand for investors of $1,500 or more.

You should read the Offering Circular and Risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Prices subject to change

Futurism fans: To create this content, a non-editorial team worked with an affiliate partner. We may collect a small commission on items purchased through this page. This post does not necessarily reflect the views or the endorsement of the Futurism.com editorial staff.

Share This Article